QQQ   423.32 (-0.59%)
AAPL   166.93 (-0.64%)
MSFT   405.46 (-1.55%)
META   502.30 (+1.65%)
GOOGL   156.26 (+0.51%)
AMZN   179.19 (-1.15%)
TSLA   150.47 (-3.20%)
NVDA   845.58 (+0.62%)
AMD   154.32 (+0.19%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.23 (+0.68%)
F   12.03 (-0.08%)
MU   112.61 (-3.20%)
GE   153.77 (-1.22%)
CGC   8.15 (+25.58%)
DIS   112.95 (+0.01%)
AMC   2.93 (-1.68%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.37 (-0.22%)
QQQ   423.32 (-0.59%)
AAPL   166.93 (-0.64%)
MSFT   405.46 (-1.55%)
META   502.30 (+1.65%)
GOOGL   156.26 (+0.51%)
AMZN   179.19 (-1.15%)
TSLA   150.47 (-3.20%)
NVDA   845.58 (+0.62%)
AMD   154.32 (+0.19%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.23 (+0.68%)
F   12.03 (-0.08%)
MU   112.61 (-3.20%)
GE   153.77 (-1.22%)
CGC   8.15 (+25.58%)
DIS   112.95 (+0.01%)
AMC   2.93 (-1.68%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.37 (-0.22%)
QQQ   423.32 (-0.59%)
AAPL   166.93 (-0.64%)
MSFT   405.46 (-1.55%)
META   502.30 (+1.65%)
GOOGL   156.26 (+0.51%)
AMZN   179.19 (-1.15%)
TSLA   150.47 (-3.20%)
NVDA   845.58 (+0.62%)
AMD   154.32 (+0.19%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.23 (+0.68%)
F   12.03 (-0.08%)
MU   112.61 (-3.20%)
GE   153.77 (-1.22%)
CGC   8.15 (+25.58%)
DIS   112.95 (+0.01%)
AMC   2.93 (-1.68%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.37 (-0.22%)
QQQ   423.32 (-0.59%)
AAPL   166.93 (-0.64%)
MSFT   405.46 (-1.55%)
META   502.30 (+1.65%)
GOOGL   156.26 (+0.51%)
AMZN   179.19 (-1.15%)
TSLA   150.47 (-3.20%)
NVDA   845.58 (+0.62%)
AMD   154.32 (+0.19%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.23 (+0.68%)
F   12.03 (-0.08%)
MU   112.61 (-3.20%)
GE   153.77 (-1.22%)
CGC   8.15 (+25.58%)
DIS   112.95 (+0.01%)
AMC   2.93 (-1.68%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.37 (-0.22%)
Free Trial
NASDAQ:IPXL

Impax Laboratories (IPXL) Stock Price, News & Analysis

→ Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad)
Free IPXL Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$17.40
▼
$18.95
50-Day Range
$18.30
▼
$18.30
52-Week Range
$13.05
▼
$25.70
Volume
3.04 million shs
Average Volume
945,265 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
IPXL stock logo

About Impax Laboratories Stock (NASDAQ:IPXL)

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

IPXL Stock News Headlines

September 10, 2023 | investing.com
Impax Sustainable Allocation Fund Investor Class (PAXWX)
May 23, 2023 | seekingalpha.com
KBLB Kraig Biocraft Laboratories, Inc.
April 18, 2024 | GoldenCrest Metals (Ad)
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.
May 11, 2023 | wsj.com
Ferozsons Laboratories Ltd.
April 5, 2023 | wsj.com
Impax Ellevate Global Women's Leadership Fund;Individual Investor
April 3, 2023 | thestreet.com
Impax Stock Hits New 52-Week High (IPXL)
March 28, 2023 | financialpost.com
Impax CEO Says Funds Have Run Out of 'Investible' Green Assets
September 29, 2022 | investing.com
Morepen Laboratories Ltd (MORL)
April 18, 2024 | GoldenCrest Metals (Ad)
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.
September 9, 2022 | fool.com
Abbott Laboratories (NYSE: ABT)
July 27, 2022 | thestreet.com
Clearside Biomedical Inc. News
See More Headlines
Receive IPXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impax Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2017
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:IPXL
CUSIP
45256B10
CIK
1003642
Web
www.impaxlabs.com
Phone
(908) 947-3120
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Chintu Patel
    Co-Chief Executive Officer & Director
  • Chirag K. Patel
    President & Co-Chief Executive Officer & Director
  • Andrew S. Boyer
    Executive Vice President-Commercial Operations
  • Anastasios G. Konidaris
    Chief Financial Officer & Senior Vice President
  • Nikita Shah
    Chief Human Resources Officer & Senior VP

Key Competitors

View All Competitors

IPXL Stock Analysis - Frequently Asked Questions

How were Impax Laboratories' earnings last quarter?

Impax Laboratories, Inc. (NASDAQ:IPXL) released its quarterly earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The specialty pharmaceutical company earned $206.40 million during the quarter, compared to analysts' expectations of $208.38 million. The firm's revenue was down 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.37 EPS.

What other stocks do shareholders of Impax Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Impax Laboratories investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NovoCure (NVCR), BlackRock Capital Investment (BKCC), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Viper Energy (VNOM) and Roper Technologies (ROP).

This page (NASDAQ:IPXL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Next President (Not Trump. Not Biden.)
The Freeport Society
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The only accurate crypto trading system I know …
Weiss Ratings